Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat versus recombinant human erythropoietin for anemia in dialysis-dependent stage 5 chronic kidney disease
ChiCTR2300071087Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Shantou University Medical College
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of roxadustat and erythropoietin in anemia of chronic kidney disease (2 arms), sponsored by The Second Affiliated Hospital of Shantou University Medical College. Primary endpoints: hemoglobin, red blood cells and 9 more. Planned start May 2023; status: not yet recruiting.
02
Drugs
roxadustaterythropoietin
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on ChiCTR2300071087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071087.